US Approval For Peanut Allergy Therapy Palforzia
Restrictions Could Limit Uptake
Executive Summary
Aimmune has secured approval for the first ever peanut allergy treatment, but safety, cost and administration issues could limit the drug's uptake.
You may also be interested in...
England’s NICE Okays First Ever Peanut Allergy Treatment Palforzia
Aimmune Therapeutics secures agreement with NHS for “step change” in treating peanut allergy.
Spotlight On Novartis's Latest Potential Breakthrough Treatments
Last week, the Swiss major gave a glimpse into the next wave of innovation coming out of its labs in key areas such as osteoarthritis, pancreatic cancer and food allergy. Scrip has been taking a detailed look at the highlights.
DBV Soars As Path For Peanut Allergy Patch Approval Clears
The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.